Novel ECG Measures and Risk of Sudden Cardiac Death
Novel ECG Measures and Risk of Sudden Cardiac Death
批准号:
8825630
负责人:
Larisa Gennadievna Tereshchenko
金额:
$37.33万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-01 至 2017-03-31
关键词:
AccountingAdultAgeAtherosclerosisAutopsyBiometryBundle-Branch BlockCardiacCardiologyCardiovascular systemCause of DeathCellsCessation of lifeCicatrixClassificationClinicalCohort StudiesCommunitiesComputer softwareCoronary heart diseaseCouplingDepressed moodDevelopmentEchocardiographyElectrocardiogramElectrophysiology (science)EpidemiologyFrequenciesFunctional disorderFundingFutureGenderGeneral PopulationGenesGeneticHealthHeartHeart DiseasesHeart RateHuman GeneticsInterventionLaboratoriesLeadLeftLeft Ventricular HypertrophyMeasuresMetricMolecularNatural HistoryPathologicPatientsPersonsPhenotypePopulationPopulations at RiskPreventionPropertyPublic HealthRaceRestRiskRisk EstimateRisk FactorsRisk MarkerSourceStratificationTechniquesTestingUnited States National Institutes of HealthVariantVentricularVentricular ArrhythmiaVentricular FibrillationVisitbasecase controlcohortdigitalfollow-upgenome wide association studyheart cellheart disease riskhigh riskimprovedmortalitynotch proteinnovelpreventprospectiverepositorysudden cardiac deathtooltrait
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Sudden cardiac death (SCD) is a major public health concern, accounting for 400,000 deaths in
the US each year. Clinical and autopsy studies have consistently demonstrated a predominant,
common pathophysiology in Western populations, showing that the most common
electrophysiologic mechanism for SCD is ventricular fibrillation (VF) and the most common
pathologic substrate is coronary heart disease (CHD). In about half of SCD cases, death is the
first clinical manifestation of CHD. Yet risk factors of SCD early in the natural history of
conditions predisposing SCD have not been fully identified, and SCD risk stratification strategy
in general population has not been developed. ECG is easy available, non-expensive and noninvasive
tool, which carries valuable information on electrophysiological properties of the heart.
However, traditional analysis of ECG includes very limited assessment of the arrhythmogenic
substrate. Recently we developed novel 12-lead ECG SCD risk score, composed of parameters
that measure (1) slow discontinued conduction, (2) temporal repolarization lability, and (3)
adverse electrical remodeling. Preliminary gender-, race-, and age-matched case-control
analysis of the Atherosclerosis In Community (ARIC) study showed a total continuous net
reclassification improvement of 86.0% as compared to the Framingham risk score alone. We
hypothesize that (1) the SCD ECG risk score, comprised of the mechanistic ECG markers of
arrhythmogenic substrate derived in the resting 12-lead ECG analysis accurately stratify
persons into high-, intermediate- and low-risk groups and improve classification in comparison
to the risk stratification on the basis of traditional CHD risk factors; (2) heritable factors of the
novel ECG phenotype are associated with the increased SCD risk. This application bridges a
critical gap between understanding of the SCD mechanisms and SCD risk stratification in a
general population. We will leverage 2 unique large NIH-funded prospective community-dwelling
GWAS cohorts with an available digital 12-lead ECG repository: ARIC and CHS. Baseline digital
12-lead ECG will be analyzed by customized Matlab software in PIs laboratory. The SCD ECG
risk score will be developed in ARIC and validated in the CHS cohort. Net reclassification
improvement will be assessed. Longitudinal changes in studied ECG parameters over 20 years
of follow-up will be evaluated as predictors of cardiac structural and functional phenotype,
assessed by echocardiography at the 5th ARIC visit. Our study will identify genes, associated
with specific ECG traits, which will lead to novel targets for treatments and in the future will
enable SCD prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel ECG Measures and Risk of Sudden Cardiac Death
-
批准号:8595389
-
项目类别:
-
资助金额:$40.55万
-
财政年份:2013
-
负责人:Larisa Gennadievna Tereshchenko
-
依托单位:
海外基金